Editas Medicine

EDITNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$442.311 M

$2.88 -0.69%

Close of 7 Aug 2026

Revenue

$40.5M

#2807 by revenue

Earnings

-$160.1M

Loss-making

Shares outstanding

153,580,035

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#71Kyverna TherapeuticsKYTX$483.9M
#72Cabaletta BioCABA$454.9M
#73Editas MedicineEDIT$442.3M
#74X4 PharmaceuticalsXFOR$437.6M
#75OcugenOCGN$434.1M

Where these numbers come from

Share counts and financials for Editas Medicine are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.